XFOR Operating Margin from 2010 to 2026

XFOR Stock

USD 3.69 -0.19 -4.90%

Operating Profit Margin is evolving in a losing momentum direction across reporting periods. Estimates suggest moderation to -17.19 this year.

Financial statement trends for X4 Pharmaceuticals provide structured context on operating performance and capital structure. The series highlights drivers like Interest Income of 7 M, Depreciation And Amortization of 466.1 K or Interest Expense of 10.6 M and ratios such as Price To Sales Ratio of 27.3, Dividend Yield of 0.0 or PTB Ratio of 6.29, complementing X4 Pharmaceuticals Valuation and Volatility.

Build AI portfolio with XFOR Stock

X4 Pharmaceuticals Correlation provides competitor comparison context for X4 Pharmaceuticals. This supports competitive context.

Ready to invest in XFOR Stock? Our How to Invest in X4 Pharmaceuticals guide walks you through the process.

Evaluating X4 Pharmaceuticals's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into X4 Pharmaceuticals's fundamental strength.

Latest X4 Pharmaceuticals' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of X4 Pharmaceuticals over the last few years. It is X4 Pharmaceuticals' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in X4 Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported -12.81 %

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Profit Margin

Timeline

XFOR Operating Margin Regression Statistics

	Arithmetic Mean	-14.61
	Coefficient Of Variation	-16.03
	Mean Deviation	1.77
	Median	-13.11
	Standard Deviation	2.34
	Sample Variance	5.49
	Range	6.848
	R-Value	-0.51
	Mean Square Error	4.34
	R-Squared	0.26
	Significance	0.04
	Slope	-0.24
	Total Sum of Squares	87.77

XFOR Operating Margin History

	2026	-17.19
	2025	-16.37
	2021	-14.24
	2019	-19.96

Stock Overview, Methodology & Data Sources

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company was founded in 2010 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. This stock section frames X4 Pharmaceuticals within its peer set and highlights how fundamentals align with price behavior. Current metrics include P/B of 5.24, profit margin of -2.8%. X4 Pharmaceuticals has a market cap of 322.64 M, ROE of -1.57%.

Methodology

Unless otherwise specified, financial data for X4 Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. XFOR (USA Stocks:XFOR) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

X4 Pharmaceuticals is covered by 4 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Goldman Sachs, Citigroup, Raymond James, Deutsche Bank, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Michael Smolkin - Member of Macroaxis Board of Directors

Pair Trading with X4 Pharmaceuticals

Pair trading with X4 Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.

Moving against XFOR Stock

0.54	AIQUY	Air Liquide SA	Pair Corr
0.52	BTI	British American Tobacco	Pair Corr
0.49	GILD	Gilead Sciences	Pair Corr
0.48	NAUT	Nautilus Biotechnology	Pair Corr
0.47	AMGN	Amgen Inc	Pair Corr

Sophisticated investors use correlation analysis to build X4 Pharmaceuticals replacement strategies that go beyond simple sector matching. Assets with similar factor exposures to X4 Pharmaceuticals provide the most accurate portfolio substitution during tax-loss harvesting periods.

Statistical correlation between X4 Pharmaceuticals and its peers is an essential input for mean-variance portfolio optimization. Lower correlation of X4 Pharmaceuticals with other holdings allows for a more efficient frontier with superior risk-adjusted returns.

Correlation analysis and pair evaluation for X4 Pharmaceuticals can support hedging context. This approach is commonly reviewed within sectors and across broader groups.

Pair Correlation Correlation Matching

Additional Tools for XFOR Stock Analysis

	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing
	Stocks Directory Find actively traded stocks across global markets
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC